The challenge stems from the nature of TCR recognition itself. Naturally occurring TCRs often bind tumor antigens with suboptimal affinity, and simply boosting binding strength can backfire, reducing specificity and raising the risk of off-target attacks on healthy tissue. Affinity enhancement strategies have historically produced receptors that cross-react with unrelated peptides, a potentially lethal side effect. Writing in Frontiers in Chemical Biology, Mario Frezzini and Daniele Narzi argue that the field needs more than raw computational power; it needs mechanistic understanding, a way of knowing not just which receptor variants bind well, but why they bind well and what molecular consequences each mutation carries.

Artificial intelligence has transformed the search for better TCRs in recent years. Deep learning models can explore vast stretches of TCR sequence space, predicting which amino acid sequences are compatible with a desired structural framework and generating libraries of candidate variants in silico. Structure-based deep learning approaches have shown genuine promise in proposing receptor variants with improved binding properties. But these tools, the authors contend, are largely data-driven and descriptive: they rely on static structural representations and scoring functions that fail to capture the dynamic, ever-fluctuating nature of protein-protein interactions. The result is an embarrassment of riches—thousands of candidates that are difficult to prioritize, and little insight into the physical determinants of recognition.

Molecular dynamics simulations sit at the opposite end of the spectrum. By explicitly modeling every atom of a TCR-peptide-MHC complex as it jiggles, flexes, and interacts in a simulated watery environment, MD reveals conformational plasticity, residue-specific energetic contributions, and the cooperative behavior of the binding interface. Decades of simulation work have shown that TCR recognition is anything but a rigid lock-and-key event; the complementarity-determining regions, the receptor’s antigen-grasping loops, fluctuate significantly, contributing to both adaptability and specificity. The catch is computational cost. Reliable MD characterization demands all-atom simulations under physiological conditions, roughly ten independent replicas per system, and sampling times of at least hundreds of nanoseconds per replica to reach statistical convergence. That makes MD suitable for analyzing only a few tens of closely related variants, not for screening hundreds of candidates.

Rather than viewing these limitations as weaknesses, Frezzini and Narzi propose exploiting them deliberately. In their framework, MD is positioned as a low-throughput, high-information filter—a step that examines a carefully chosen handful of candidates in exquisite detail. The pipeline begins with biologically grounded receptor selection: repertoire sequencing of tumor-infiltrating lymphocytes, peripheral blood, or antigen-specific T cell populations, combined with bioinformatic analysis of clonal expansion, persistence, and CDR3 sequence similarity, identifies candidate receptors with known or putative tumor reactivity. AI-driven design then explores the local sequence space around these validated scaffolds, generating variant libraries. Fast pre-screening tools—empirical scoring functions, rapid energetic estimates, or machine learning predictors—trim the candidate pool to a manageable size before the expensive physics-based refinement begins.

At the heart of the workflow, MD serves as an integrative mechanistic engine rather than a brute-force screener. Trajectory analyses quantify how flexibly the CDR loops move, which interaction patterns stabilize the complex over time, and, through residue-specific energy decomposition schemes, which individual amino acids contribute favorably to binding. Crucially, the simulations also map allosteric communication pathways—networks of dynamically coupled residues that connect the binding interface to distal regions of the receptor. Local perturbations can propagate through the structure and modulate the behavior of residues tens of angstroms away, meaning that mutations in one part of the receptor can reshape binding chemistry at another. This dual description of energetics and allostery gives the pipeline a mechanistic criterion for prioritizing variants that goes far beyond static sequence-based metrics.

The power of this approach is illustrated by the authors’ own recent computational work on a pair of closely related engineered TCRs, c796 and its parent c728. The two receptors differ by a single conservative mutation, E31D, in the CDR1 loop, yet experiments show the variant binds its target peptide-MHC complex roughly six-fold more tightly. Counterintuitively, detailed energetic analysis revealed that the mutated residue itself contributes nothing directly to the improved affinity. Instead, the single substitution triggers a redistribution of interaction energies across multiple residues, including positions in distal CDR loops that now stabilize the interface more favorably. Network analyses of simulation trajectories traced allosteric pathways linking the mutation site to these distant regions. In other words, binding affinity in TCR systems emerges from a cooperative web of interactions, and even a minimal sequence change can produce substantial functional consequences through dynamic, long-range mechanisms—precisely the kind of hidden logic that only MD-based mechanistic analysis can expose.

The framework’s final stage returns to the laboratory, where two complementary experimental technologies validate the computationally refined candidates. Surface plasmon resonance, the gold standard for biophysical characterization, directly measures the association and dissociation rates of TCR-peptide-MHC binding, providing quantitative affinity and kinetic parameters for a limited set of high-confidence variants. But SPR requires recombinant protein expression and purification, offers relatively low throughput, and cannot capture the conformational and energetic complexity that governs T cell activation. That gap is filled by cellular reporter assays such as RAPTR, which evaluate TCR activation in response to specific peptide-MHC complexes within a living cellular environment, capturing downstream signaling and functional output at higher throughput. Importantly, binding affinity alone does not necessarily correlate with functional efficacy, so these orthogonal layers of validation—molecular binding on one side, cellular function on the other—are essential for identifying receptors that are both strong and clinically useful.

What distinguishes the proposed strategy from previous pipelines is its iterative, bidirectional character. Energetic fingerprints and allosteric maps derived from MD are fed back into the AI design models, narrowing and sharpening the sequence space they explore in the next round. Experimental results, in turn, benchmark and improve the computational predictions. The authors describe this as a closed-loop, multi-scale design paradigm, building on recent demonstrations that lab-in-the-loop AI-guided optimization can work for therapeutic antibody engineering. Emerging generative tools such as AlphaFlow and BioEmu may eventually accelerate conformational sampling upstream, and the authors envision hybrid strategies in which AI-generated structural ensembles initialize diverse conformations for explicit-solvent MD refinement—though they caution that these newer methods have not yet been validated for multichain TCR-peptide-MHC complexes or mutation-induced energy changes.

The approach is not without caveats. MD-based mechanistic insight is only as reliable as the structural model underlying the simulations, and accurate models of TCR-peptide-MHC complexes remain challenging to obtain because of the intrinsic flexibility of the CDR loops and the complexity of protein-protein recognition. AI tools like AlphaFold have improved structural prediction enormously, but performance for receptor-ligand complexes is still limited without experimental structural data. The authors therefore stress that every mechanistic hypothesis generated in silico must be experimentally validated before guiding the next round of optimization. If the framework delivers on its promise, however, the payoff could be substantial: a scalable, adaptive design engine that unifies statistical learning with physical principles, capable of producing the high-affinity, exquisitely specific, and safe T cell receptors that next-generation cancer immunotherapy demands. The convergence of AI, molecular dynamics, and experimental validation may finally turn TCR engineering from an empirical art into a predictive science.

Subject of Research: Integrating artificial intelligence, molecular dynamics simulations, and experimental assays for mechanism-aware engineering of T cell receptors in cancer immunotherapy

Article Title: Bridging AI, molecular dynamics, and experiments for mechanism-aware TCR engineering in cancer immunotherapy

Article References: Frezzini, M., & Narzi, D. (2026). Bridging AI, molecular dynamics, and experiments for mechanism-aware TCR engineering in cancer immunotherapy. Frontiers in Chemical Biology, 5, Article 1909618. https://doi.org/10.3389/fchbi.2026.1909618

Image Credits: AI Generated

DOI: 10.3389/fchbi.2026.1909618

Keywords: T cell receptor engineering, cancer immunotherapy, artificial intelligence, molecular dynamics simulations, allosteric communication, peptide-MHC complex, surface plasmon resonance, RAPTR assay, protein design, adoptive T cell therapy, binding affinity, computational biology